title: [Multiple enlarged metabolically active lymph nodes in 18F-FDG PET/CT after anti-CTLA-4 antibody therapy in metastatic melanoma - disease progression or immunologically induced side effect?].
authors.forename: S C
authors.initials: SC
authors.lastname: Schüle
authors.forename: T
authors.initials: T
authors.lastname: Eigentler
authors.forename: C
authors.initials: C
authors.lastname: Pfannenberg
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D003106:Colon / Q000000981:diagnostic imaging; D003937:Diagnosis, Differential; D018450:Disease Progression; D004734:Energy Metabolism / Q000502:physiology*; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D000074324:Ipilimumab; D008198:Lymph Nodes / Q000000981:diagnostic imaging*; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D064847:Multimodal Imaging / Q000379:methods*; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000188:drug therapy* / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods*; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D000074324:Ipilimumab; D019788:Fluorodeoxyglucose F18